The Association between Macroprolactin Levels and Vitamin D Status in Premenopausal Women with Macroprolactinemia: A Pilot Study

R. Krysiak; B. Kowalska; W. Szkróbka; B. Okopień

doi:10.1055/s-0035-1555877

Experimental and Clinical Endocrinology & Diabetes, Table of Contents

Exp Clin Endocrinol Diabetes 2015; 123(08): 446-450
DOI: 10.1055/s-0035-1555877

Article

The Association between Macroprolactin Levels and Vitamin D Status in Premenopausal Women with Macroprolactinemia: A Pilot Study

Authors

R. Krysiak

¹Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland
B. Kowalska

¹Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland

²Department of Endocrinology, Provincial Hospital, Opole, Poland
W. Szkróbka

¹Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland
B. Okopień

¹Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland

Abstract

Background: Macroprolactinemia is a frequent cause of misdiagnosis and mismanagement of patients with elevated prolactin levels. Its pathogenesis and clinical significance are still controversial.

Methods: The aim of this study was to investigate the relationship between elevated macroprolactin content and vitamin D status. The study population included 20 premenopausal women with isolated macroprolactinemia, 10 of whom were later treated with vitamin D (2 000 IU daily). Serum prolactin, macroprolactin, 25-hydroxyvitamin D and PTH levels were assessed at baseline and after 4 months of treatment.

Results: Compared with the control age- and weight-women with normal prolactin levels (n=11), patients with macroprolactinemia were characterized by lower levels of 25-hydroxyvitamin D and slightly higher levels of PTH. Vitamin D administered to patients with macroprolactinemia increased 25-hydroxyvitamin, reduced total prolactin and macroprolactin, as well tended to reduce PTH. The effect of vitamin D on total prolactin and macroprolactin correlated with their baseline values and baseline 25-hydroxyvitamin D levels.

Conclusions: The results of our study suggest the association between vitamin D status and elevated macroprolactin levels in premenopausal women.

Key words

vitamin D - hyperprolactinemia - macroprolactinemia - polyethylene glycol assay

Full Text

References

References
1 Schiettecatte J, Van Opdenbosch A, Anckaert E et al. Immunoprecipitation for rapid detection of macroprolactin in the form of prolactin-immunoglobulin complexes. Clin Chem 2005; 51: 1746-1778
2 Fahie-Wilson MN, John R, Ellis AR. Macroprolactin; high molecular mass forms of circulating prolactin. Ann Clin Biochem 2005; 42: 175-192
3 Shimatsu A, Hattori N. Macroprolactinemia: diagnostic, clinical, and pathogenic significance. Clin Dev Immunol 2012; 2012: 167132
4 Kasum M, Pavičić-Baldani D, Stanić P et al. Importance of macroprolactinemia in hyperprolactinemia. Eur J Obstet Gynecol Reprod Biol 2014; 183: 28-32
5 Gibney J, Smith TP, McKenna TJ. Clinical relevance of macroprolactin. Clin Endocrinol (Oxf) 2005; 62: 633-643
6 Malarkey WB, Jackson R, Wortsman J. Long-term assessment of patients with macroprolactinemia. Fertil Steril 1988; 50: 413-418
7 Leite V, Cosby H, Sobrinho LG et al. Characterization of big, big prolactin in patients with hyperprolactinaemia. Clin Endocrinol (Oxf) 1992; 37: 365-372
8 Leaños-Miranda A, Pascoe-Lira D, Chávez-Rueda KA et al. Detection of macroprolactinemia with the polyethylene glycol precipitation test in systemic lupus erythematosus patients with hyperprolactinemia. Lupus 2001; 10: 340-345
9 Vallette-Kasic S, Morange-Ramos I, Selim A et al. Macroprolactinemia revisited: a study on 106 patients. J Clin Endocrinol Metab 2002; 87: 581-588
10 Kavanagh-Wright L, Smith TP, Gibney J et al. Characterization of macroprolactin and assessment of markers of autoimmunity in macroprolactinaemic patients. Clin Endocrinol (Oxf) 2009; 70: 599-605
11 De Bellis A, Bizzarro A, Pivonello R et al. Prolactin and autoimmunity. Pituitary 2005; 8: 25-30
12 Orbach H, Shoenfeld Y. Hyperprolactinemia and autoimmune diseases. Autoimmun Rev 2007; 6: 537-542
13 Vera-Lastra O, Jara LJ, Espinoza LR. Prolactin and autoimmunity. Autoimmun Rev 2002; 1: 360-364
14 Vanoirbeek E, Krishnan A, Eelen G et al. The anti-cancer and anti-inflammatory actions of 1,25(OH)₂D₃. Best Pract Res Clin Endocrinol Metab 2011; 25: 593-604
15 Bozkurt NC, Karbek B, Ucan B et al. The association between severity of vitamin D deficiency and Hashimoto’s thyroiditis. Endocr Pract 2013; 19: 479-484
16 Krysiak R, Okopien B. Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels. Basic Clin Pharmacol Toxicol 2014; Aug 13
17 Orbach H, Zandman-Goddard G, Amital H et al. Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. Ann N Y Acad Sci 2007; 1109: 385-400
18 Keisala T, Minasyan A, Järvelin U et al. Aberrant nest building and prolactin secretion in vitamin D receptor mutant mice. J Steroid Biochem Mol Biol 2007; 104: 269-273
19 Akerström G, Hellman P, Hessman O et al. Parathyroid glands in calcium regulation and human disease. Ann N Y Acad Sci 2005; 1040: 53-58
20 Millen AE, Bodnar LM. Vitamin D assessment in population-based studies: a review of the issues. Am J Clin Nutr 2008; 87: 1102S-1105S
21 Mounier C, Trouillas J, Claustrat B et al. Macroprolactinaemia associated with prolactin adenoma. Hum Reprod 2003; 18: 853-857
22 Tamer G, Telci A, Mert M et al. Prevalence of pituitary adenomas in macroprolactinemic patients may be higher than it is presumed. Endocrine 2012; 41: 138-143
23 Brown DJ, Spanos E, MacIntyre I. Role of pituitary hormones in regulating renal vitamin D metabolism in man. Br Med J 1980; 280: 277-278
24 Lips P. Vitamin D physiology. Prog Biophys Mol Biol 2006; 92: 4-8
25 Lin R, White JH. The pleiotropic actions of vitamin D. Bioessays 2004; 26: 21-28
26 Kasum M, Oreskovic S, Zec I et al. Macroprolactinemia: new insights in hyperprolactinemia. Biochem Med (Zagreb) 2012; 22: 171-179
27 Olukoga AO. Macroprolactinemia is clinically important. J Clin Endocrinol Metab 2002; 87: 4833-4834
28 Guillot X, Semerano L, Saidenberg-Kermanach N et al. Vitamin D and inflammation. Joint Bone Spine 2010; 77: 552-557
29 Krysiak R, Kowalska B, Okopien B. Serum 25-hydroxyvitamin D and parathyroid hormone levels in non-lactating women with post-partum thyroiditis: the effect of L-thyroxine treatment. Basic Clin Pharmacol Toxicol 2014; Nov 14
30 Krysiak R, Kowalska B, Szkrobka W et al. The effect of oral contraception on macroprolactin levels in women with macroprolactinemia: a pilot study. Pharmacol Rep (accepted)
31 Zofková I, Nedvídková J. Effect of 1,25-dihydroxyvitamin D3 (calcitriol) on prolactin secretion at rest and TRH-stimulated secretion in humans. Exp Clin Endocrinol 1988; 91: 207-211
32 Díaz L, Martínez-Reza I, García-Becerra R et al. Calcitriol stimulates prolactin expression in non-activated human periphe ral blood mononuclear cells: breaking paradigms. Cytokine 2011; 55: 188-194
33 Christin-Maître S, Delemer B, Touraine P et al. Prolactinoma and estrogens: pregnancy, contraception and hormonal replacement therapy. Ann Endocrinol (Paris) 2007; 68: 106-112
34 Hattori N, Adachi T, Ishihara T et al. The natural history of macroprolactinaemia. Eur J Endocrinol 2012; 166: 625-629
35 Gozdzik A, Barta JL, Weir A et al. Serum 25-hydroxyvitamin D concentrations fluctuate seasonally in young adults of diverse ancestry living in Toronto. J Nutr 2010; 140: 2213-2220